Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.51 |
| ▸ | STS | P08842 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | JAK1 | P23458 | 1/20 | 0.51 |
| ▸ | TACR1 | P25103 | 1/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL517515 | 1.00 | USP30 (0.53) | USP30GPR119STSJAK2JAK1 | |
| SCHEMBL2292403 | 1.00 | USP30 (0.53) | USP30GPR119STSJAK2JAK1 | |
| SCHEMBL26077407 | 1.00 | USP30 (0.53) | USP30GPR119STSJAK2JAK1 | |
| SCHEMBL2273817 | 1.00 | USP30 (0.53) | USP30GPR119STSJAK2JAK1 | |
| SCHEMBL5768083 | 1.00 | USP30 (0.53) | USP30GPR119STSJAK2JAK1 | |
| SCHEMBL2292408 | 1.00 | USP30 (0.53) | USP30GPR119STSJAK2JAK1 | |
| SCHEMBL20766014 | 0.90 | DNMT3A (0.46) | USP30GPR119TACR1TP53 | |
| SCHEMBL29673228 | 0.90 | DNMT3A (0.46) | USP30GPR119TACR1TP53 | |
| SCHEMBL20778648 | 0.90 | DNMT3A (0.46) | USP30GPR119TACR1TP53 | |
| SCHEMBL20794795 | 0.90 | DNMT3A (0.46) | USP30GPR119TACR1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112384509-B | Furin inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2024-04-30 | — | — | CN | disclosed |
| EP-2367800-B9 | SUBSTITUTED PYRIMIDINES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | IPHARMA H K LTD (HK) | 2021-10-20 | — | — | EP | disclosed |
| CN-112384509-A | Furin inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-02-19 | — | — | CN | disclosed |
| EP-3512837-B1 | PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INT (DE) | 2020-07-22 | — | — | EP | disclosed |
| EP-3512837-B1 | PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INT (DE) | 2020-07-22 | — | — | EP | disclosed |
| US-10138222-B2 | Substituted benzamides as RIPK2 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-11-27 | — | — | US | disclosed |
| WO-2018052773-A1 | PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-22 | — | — | WO | disclosed |
| US-20180072703-A1 | PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-15 | — | — | US | disclosed |
| US-20180072703-A1 | PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-15 | — | — | US | disclosed |
| US-20180072703-A1 | PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-15 | — | — | US | disclosed |
| US-7312212-B2 | Aminopiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2007-12-25 | — | — | US | disclosed |
| US-7109213-B2 | Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them | GLAXO GROUP LIMITED (GB) | 2006-09-19 | — | — | US | disclosed |
| US-20060058287-A1 | Gramnegative and Grampositive bacterial infections; substituted Piperidine derivatives specially optionally substituted pyrido [3,2, -b][1,4] thiazin-yl; 6-({(3R,4S)-3-Fluoro-1-[(R)-2-hydroxy-2-(2-methoxy-quinolin-8-yl)-ethyl]-piperidin-4-ylamino }-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one; nontoxic | GLAXO GROUP LIMITED (GB) | 2006-03-16 | — | — | US | disclosed |
| US-20060041123-A1 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
| EP-1583537-A3 | PIPERIDINE COMPOUNDS AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2005-12-14 | — | — | EP | disclosed |
| EP-1583537-A2 | PIPERIDINE COMPOUNDS AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2005-10-12 | — | — | EP | disclosed |
| US-20050159411-A1 | Aminopiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2005-07-21 | — | — | US | disclosed |
| US-20050085494-A1 | Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them | GLAXO GROUP LIMITED (GB) | 2005-04-21 | — | — | US | disclosed |
| WO-2004002490-A2 | PIPERIDINE COMPOUNDS AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2004-01-08 | — | — | WO | disclosed |
| US-5837715-A | 3-fluoro-4-aminopiperidine derivatives as 5-HT receptor agonists | MERCK SHARP & DOHME LTD. (GB) | 1998-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10138222-B2 | Substituted benzamides as RIPK2 inhibitors | RIPK2, RIPK4, RIPK1 | USP30 1584/4885GPR119 603/4885STS 2132/4885 |
| US-20050085494-A1 | Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them | NPEPPS, AASDHPPT, DNPEP | USP30 3815/4885GPR119 541/4885STS 4412/4885 |
| US-20060041123-A1 | Antibacterial agents | NQO2, NRDC, IFNG | USP30 2980/4885GPR119 4545/4885STS 2567/4885 |
| US-20180072703-A1 | PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF RIPK2 | RIPK2, RIPK1, RIPK4 | USP30 2218/4885GPR119 770/4885STS 3438/4885 |
| US-20050159411-A1 | Aminopiperidine derivatives | AMPD2, AMPD3, NPEPPS | USP30 3209/4885GPR119 2446/4885STS 4352/4885 |
| US-20060058287-A1 | Gramnegative and Grampositive bacterial infections; substituted Piperidine derivatives specially optionally substituted pyrido [3,2, -b][1,4] thiazin-yl; 6-({(3R,4S)-3-Fluoro-1-[(R)-2-hydroxy-2-(2-methoxy-quinolin-8-yl)-ethyl]-piperidin-4-ylamino }-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one; nontoxic | TLR1, TLR2, TLR6 | USP30 4241/4885GPR119 2486/4885STS 3475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.